Dr. Andrew Y. Kee, MD | Portland, OR ...

Dr. Andrew Y. Kee

Claim this profile

Legacy Good Samaritan Hospital and Medical Center

Studies Brain Tumor
Studies Lung Cancer
19 reported clinical trials
60 drugs studied

Area of expertise

1Brain Tumor
Andrew Y. Kee has run 5 trials for Brain Tumor. Some of their research focus areas include:
Stage IV
IDH positive
1p/19q co-deletion positive
2Lung Cancer
Andrew Y. Kee has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.
Legacy Good Samaritan Hospital And Medical Center
Image of trial facility.
Legacy Mount Hood Medical Center

Clinical Trials Andrew Y. Kee is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Stereotactic Radiosurgery vs. HA-WBRT + Memantine

for Brain Cancer

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Recruiting2 awards Phase 3

More about Andrew Y. Kee

Clinical Trial Related3 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Andrew Y. Kee has experience with
  • Radiation Therapy
  • Cisplatin
  • Atezolizumab
  • Paclitaxel
  • Intensity-Modulated Radiation Therapy
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Andrew Y. Kee specialize in?
Is Andrew Y. Kee currently recruiting for clinical trials?
Are there any treatments that Andrew Y. Kee has studied deeply?
What is the best way to schedule an appointment with Andrew Y. Kee?
What is the office address of Andrew Y. Kee?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security